Home/Filings/4/0001209191-22-042900
4//SEC Filing

Lang Daniel 4

Accession 0001209191-22-042900

CIK 0001300699other

Filed

Jul 20, 8:00 PM ET

Accepted

Jul 21, 5:28 PM ET

Size

10.5 KB

Accession

0001209191-22-042900

Insider Transaction Report

Form 4
Period: 2022-07-20
Lang Daniel
Pres Cell Therapy, VP Corp Dev
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-07-20+200,000200,000 total
    Exercise: $0.67Exp: 2032-07-20Common Stock (200,000 underlying)
Holdings
  • Stock Option (Right to Buy)

    Exercise: $10.25Exp: 2030-08-27Common Stock (40,000 underlying)
    40,000
  • Stock Option (Right to Buy)

    Exercise: $2.77Exp: 2031-09-16Common Stock (50,000 underlying)
    50,000
  • Restricted Stock Units

    Common Stock (50,000 underlying)
    50,000
  • Common Stock

    73,413
Footnotes (6)
  • [F1]Includes 30,000 shares subject to a restricted stock award vesting in four equal annual installments beginning on August 26, 2020.
  • [F2]This option vests in four equal annual installments beginning on August 27, 2021.
  • [F3]This option vests in four equal annual installments beginning on September 16, 2022.
  • [F4]Each restricted stock unit represents a contingent right to receive one share of stock.
  • [F5]The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
  • [F6]This option vests in four equal annual installments beginning on July 20, 2023.

Issuer

Athenex, Inc.

CIK 0001300699

Entity typeother

Related Parties

1
  • filerCIK 0001895384

Filing Metadata

Form type
4
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 5:28 PM ET
Size
10.5 KB